New drug combo studied for tough prostate cancer

NCT ID NCT02123758

Ongoing Disease control Sponsor: Aragon Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 27 times

Summary

This study looked at how two prostate cancer drugs (JNJ-56021927 and abiraterone acetate) interact in the body and whether combining them is safe. It involved 57 men with metastatic castration-resistant prostate cancer, a type that no longer responds to standard hormone therapy. The goal was to understand drug levels and side effects, not to cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Study site

Los Angeles, California, United States
Study site

San Francisco, California, United States
Study site

Houston, Texas, United States
Study site

Vancouver, British Columbia, Canada
Study site

Montreal, Quebec, Canada
Study site

Rotterdam, Netherlands
Study site

Sutton, United Kingdom

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER PROSTATIC NEOPLASMS